ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3186

Foot Synovitis in Patients with Rheumatoid Arthritis in Apparent Remission Is Associated with Unstable Remission Status, Radiographic Progression and Worse Long-Term Functional Outcomes

Mihir D. Wechalekar1,2,3, Susan Lester4,5, Maureen Rischmueller6,7, Catherine Hill8,9 and Susanna Proudman1,8, 1Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 2School of Medicine, Flinders University School of Medicine, Adelaide, Australia, 3Repatriation General Hospital, Rheumatology Research Unit, Daw Park, Australia, 4Rheumatology, Basil Hetzel Institute, QEH, Woodville South, Australia, 5Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, 6Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, 7University of Adelaide, Adelaide, Australia, 8Discipline of Medicine, University of Adelaide, Adelaide, Australia, 9The Queen Elizabeth Hospital, Woodville South, South Australia, Australia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Foot care and synovitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects V: Goal = Remission

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Previous cross-sectional data revealed disease activity (DA) measures that omit foot joint assessment inadequately capture foot synovitis in in apparent remission at 6 months1. We sought to determine whether foot synovitis is associated with adverse radiographic and functional outcomes after 3 years in an inception cohort receiving treat-to-target combination DMARD therapy. 

Methods: Patients with early RA (<1 year; fulfilling ACR 1987 and/or 2010 classification criteria) were included. Remission was assessed using DAS28, clinical disease activity index (CDAI) and simplified disease activity index (SDAI); radiographic outcomes by annual hand and feet radiographs scored by the van der Heijde modified Sharp score and quality of life by SF-36. The prevalence of remission by different DA criteria and presence of foot synovitis was estimated using marginal binomial generalised estimating equations and transition between disease remission and non-remission states using a multi-state Markov model. Changes in radiographic scores were analysed using negative binomial mixed regression log-link model. SF-36 data were transformed to a norm-based scale (NBS) using population matched data and analysed by mixed effects linear regression.

Results: Baseline DA in 266 patients was 5.43 (SD 1.27). Dynamic correlation revealed DA scores that omit foot joint scores were modest in their ability to capture foot synovitis over time. Despite relative stringency of SDAI and CDAI as remission criteria, a significant proportion of patients in remission had foot synovitis, ranging from 25-36% (Table 1). In patients in apparent remission, foot synovitis predicted transition from remission into relapse by up to 2-fold (Table 2), and the sustainability of remission markedly influenced progression of erosion scores (p=0.006) After adjustment for DA, foot synovitis was associated with significantly worse SF-36 physical functioning subscale (p=0.025). 

Table 1. Proportion of patients in remission

DAS28 (CRP)

DAS28 (ESR)

SDAI

CDAI

Patients in remission, with or without foot synovitis (95%CI)

0.47

(0.11, 0.51)

0.43

(0.10, 0.47)

0.28

 (0.05, 0.32)

0.27

(0.05, 0.31)

Patients in remission with foot synovitis (95% CI)

0.35

(0.29, 0.41)

0.36

(0.30, 0.42)

0.24

(0.18, 0.30)

0.25

(0.19, 0.32)

Table 2. The effect of foot synovitis on transition from remission to non-remission and vice versa

Transition

Hazard Ratio (95% CI)

DAS28(CRP)

DAS28(ESR)

SDAI

CDAI

Non-remission to Remission

0.68

(0.42, 1.10)

0.70

(0.45, 1.10)

0.70

(0.40, 1.24)

0.68

(0.39, 1.17)

Remission to Non-remission

1.47

(0.84, 2.57)

1.81

(1.03, 3.17)

2.06

(1.00, 4.26)

2.08

(1.03, 4.18)

Likelihood Ratio test p-value

0.015

0.002

0.0004

0.0002

Conclusion:

DA measures that omit foot joints capture foot synovitis poorly. When used to define remission, a substantial proportion have foot synovitis which predicts relapse into non-remission and worse physical function. Foot synovitis influences sustainability of remission which in turn markedly influences radiographic progression. Presence of foot synovitis regardless of remission status should warrant consideration of escalation of therapy to improve long-term outcomes.

1 Wechalekar MD et al. Arthritis Rheum 2012;64:1316-22.


Disclosure: M. D. Wechalekar, None; S. Lester, None; M. Rischmueller, None; C. Hill, None; S. Proudman, None.

To cite this abstract in AMA style:

Wechalekar MD, Lester S, Rischmueller M, Hill C, Proudman S. Foot Synovitis in Patients with Rheumatoid Arthritis in Apparent Remission Is Associated with Unstable Remission Status, Radiographic Progression and Worse Long-Term Functional Outcomes [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/foot-synovitis-in-patients-with-rheumatoid-arthritis-in-apparent-remission-is-associated-with-unstable-remission-status-radiographic-progression-and-worse-long-term-functional-outcomes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/foot-synovitis-in-patients-with-rheumatoid-arthritis-in-apparent-remission-is-associated-with-unstable-remission-status-radiographic-progression-and-worse-long-term-functional-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology